Mode
Text Size
Log in / Sign up
Phase 3 Completed N=110 Randomized Quadruple-blind Treatment

Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Polycystic Kidney, Autosomal Dominant
Source: ClinicalTrials.gov NCT00456365 ↗
Enrolled (actual)
110
Serious AEs
0.0%
Results posted
Mar 2018
Primary outcomePrimary: Percent of Participants Demonstrating 20% or More Increase in Total Kidney Volume — 69; 88 percentage of participants — p=0.03
◆ Published Evidence
Emerging
8citations · ~4 / year
Interventions for preventing the progression of autosomal dominant polycystic kidney disease.
The Cochrane database of systematic reviews · 2024 · Open access · Likely link

Summary

The purpose of this study is to determine whether the medication pravastatin will ameliorate renal and cardiovascular disease over a 3-year period in children and young adults with autosomal dominant polycystic kidney disease (ADPKD).

Linked Publications

  • Interventions for preventing the progression of autosomal dominant polycystic kidney disease.
    The Cochrane database of systematic reviews · 2024 · 8 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent of Participants Demonstrating 20% or More Increase in Total Kidney Volume
69; 88 0.03 sig
SECONDARY
Percentage Change in Total Kidney Volume Corrected for Height
23; 31 0.02 sig
SECONDARY
Left Ventricular Mass Index
60; 58 0.69
SECONDARY
Urinary Albumin Excretion
29; 49 0.21

Eligibility Criteria

Inclusion Criteria

  • Age 8-22 years
  • Autosomal dominant polycystic kidney disease
  • Normal kidney function

Exclusion Criteria

  • Abnormal kidney function
  • Past allergic history to medications used in study
  • Liver disease
  • Muscle disease/dystrophy
  • Pregnancy, planned pregnancy, or lactation within study period
  • Inability to cooperate with or clinical contraindication for magnetic resonance imaging
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00456365) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search